- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05440383
A Clinical Study of KLH-2109 in Uterine Fibroids Patient With Menorrhagia
September 19, 2023 updated by: Kissei Pharmaceutical Co., Ltd.
A Phase III Confirmatory Study of KLH-2109 in Uterine Fibroids Patient With Menorrhagia
Multi-center, randomized, double-blind, parallel-group study to confirm non-inferiority of KLH-2109 to Leuprorelin acetate in uterine fibroids patient with menorrhagia
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
264
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Kissei Pharmaceutical Co., Ltd.
- Phone Number: Email only
- Email: rinsyousiken@pharm.kissei.co.jp
Study Locations
-
-
-
Multiple Locations, Japan
- Clinical Resarch Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Premenopausal Japanese woman diagnosed with uterine fibroids
- Patients confirmed by transvaginal ultrasonography to have at least 1 myoma that meet all of the following conditions:
- Larger than a certain standard
- No calcification
- Not receiving surgical treatment
- Patients with a normal menstrual cycle
- Patients diagnosed with menorrhagia
Exclusion Criteria:
- Patients with complication or history of blood system diseases (salasemia, sickle erythrocyte anemia, folic acid deficiency, coagulation disorder, etc.) (excluding iron deficiency anemia and latent iron deficiency anemia)
- Patients with lower abdominal pain due to irritable bowel syndrome or lower abdominal pain due to severe interstitial cystitis
- Patients with undiagnosed abnormal genital bleeding
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: KLH-2109
Oral administration
|
Oral administration
|
Active Comparator: Leuprorelin
Subcutaneous administration
|
Subcutaneous administration
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of subjects with a total PBAC score of less than 10 from Week 6 to 12 after beginning of study drug administration
Time Frame: Up to 12 weeks
|
PBAC (pictorial blood loss assessment chart) score
|
Up to 12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of subjects with a total PBAC score of less than 10 from Week 2 to 6 after beginning of study drug administration
Time Frame: Up to 24 weeks
|
PBAC (pictorial blood loss assessment chart) score
|
Up to 24 weeks
|
Proportion of subjects with a total PBAC score of less than 10 from Week 18 to 24 after beginning of study drug administration
Time Frame: Up to 24 weeks
|
PBAC (pictorial blood loss assessment chart) score
|
Up to 24 weeks
|
Proportion of subjects with a total PBAC score of less than 10 during 6 weeks before end of study drug administration
Time Frame: Up to 24 weeks
|
PBAC (pictorial blood loss assessment chart) score
|
Up to 24 weeks
|
Change from baseline in blood hemoglobin
Time Frame: Up to 24 weeks
|
Hemoglobin
|
Up to 24 weeks
|
Change rate from baseline in myoma volume
Time Frame: Up to 24 weeks
|
Myoma volume
|
Up to 24 weeks
|
Change rate from baseline in uterine volume
Time Frame: Up to 24 weeks
|
Uterine volume
|
Up to 24 weeks
|
Change from baseline in UFS-QOL score
Time Frame: Up to 24 weeks
|
UFS-QOL (uterine fibroid symptom and QOL) score
|
Up to 24 weeks
|
Incidence of adverse events and adverse drug reactions
Time Frame: Up to 24 weeks
|
Adverse events and adverse drug reactions
|
Up to 24 weeks
|
Change rate from baseline in bone metabolic markers (BAP and serum NTx)
Time Frame: Up to 24 weeks
|
Bone metabolic markers (BAP and serum NTx)
|
Up to 24 weeks
|
Change rate from baseline in bone density (DXA)
Time Frame: Up to 24 weeks
|
Bone density, T-score
|
Up to 24 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Yoshitaka Shimizu, Kissei Pharmaceutical Co., Ltd.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 11, 2022
Primary Completion (Estimated)
May 1, 2025
Study Completion (Estimated)
May 1, 2025
Study Registration Dates
First Submitted
June 27, 2022
First Submitted That Met QC Criteria
June 27, 2022
First Posted (Actual)
June 30, 2022
Study Record Updates
Last Update Posted (Actual)
September 21, 2023
Last Update Submitted That Met QC Criteria
September 19, 2023
Last Verified
September 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Neoplasms, Connective and Soft Tissue
- Neoplasms by Histologic Type
- Neoplasms
- Uterine Diseases
- Hemorrhage
- Connective Tissue Diseases
- Neoplasms, Connective Tissue
- Menstruation Disturbances
- Neoplasms, Muscle Tissue
- Uterine Hemorrhage
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Genital Diseases
- Genital Diseases, Female
- Leiomyoma
- Myofibroma
- Menorrhagia
- Physiological Effects of Drugs
- Antineoplastic Agents
- Antineoplastic Agents, Hormonal
- Reproductive Control Agents
- Fertility Agents, Female
- Fertility Agents
- Leuprolide
Other Study ID Numbers
- KLH2301
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Uterine Fibroids (MeSH Heading: Leiomyoma)
-
Kissei Pharmaceutical Co., Ltd.Active, not recruitingUterine Fibroids (MeSH Heading: Leiomyoma)Japan
-
Johann Wolfgang Goethe University HospitalCompletedMeSH Heading Cardiac Surgical Procedures | Tree Number E04.100.376 | Tree Number E04.928.220Germany
-
IceCure Medical Ltd.Withdrawn
-
University of California, San FranciscoUniversity of California, San Diego; University of California, Los Angeles; University... and other collaboratorsCompleted
-
University of California, San FranciscoActive, not recruitingUterine FibroidsUnited States
-
InSightecCompletedUterine Fibroids | Uterine LeiomyomaUnited States, Canada
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedUterine Leiomyomata (Fibroids)United States
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedUterine Leiomyomata (Fibroids)Japan
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedUterine Leiomyomata (Fibroids)Japan
-
Trieu, Nguyen Thi, M.D.Completed
Clinical Trials on KLH-2109
-
Kissei Pharmaceutical Co., Ltd.Active, not recruitingUterine Fibroids (MeSH Heading: Leiomyoma)Japan
-
Kissei Pharmaceutical Co., Ltd.Completed
-
Kissei Pharmaceutical Co., Ltd.Completed
-
Kissei Pharmaceutical Co., Ltd.Completed
-
Innolake BiopharmNot yet recruitingMelanoma | Soft Tissue Sarcoma | Cervical Cancer | Head and Neck Cancer | Nasopharyngeal Carcinoma | Ovarian Cancer | Non Small Cell Lung Cancer | Triple Negative Breast Cancer | Endometrial Cancer | Classic Hodgkin Lymphoma
-
MBX BiosciencesCompleted
-
Kissei Pharmaceutical Co., Ltd.Completed
-
Ono Pharmaceutical Co. LtdCompleted
-
University of NebraskaGenitope CorporationCompleted
-
Roswell Park Cancer InstituteNo longer availableGlioblastoma